Inozyme Pharma (INZY) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Inozyme Pharma Inc : Raymond James Initiates Coverage With Outperform Rating; Target Price $26
ReutersDec 12 07:35 ET
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswireNov 27 08:30 ET
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Simply Wall StNov 16 09:25 ET
Here's Why Inozyme Pharma (INZY) Is Poised for a Turnaround After Losing -29.98% in 4 Weeks
Zacks Nov 13 08:45 ET
Stifel Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $16
Moomoo NewsNov 8 10:37 ET · Ratings
H.C. Wainwright Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $14
Moomoo NewsNov 6 06:33 ET · Ratings

Comments

Jaguar8

Dec 15 20:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...

25

7

Jaguar8

Oct 24 12:15

NEWS

$Inozyme Pharma (INZY.US)$
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
Inozyme Pharma (INZY) announced positive interim data from its Phase 1 SEAPORT 1 trial of INZ-701 in patients with end-stage kidney disease (ESKD) undergoing hemodialysis. The trial demonstrated that INZ-701 significantly increased plasma pyrophosphate (PPi) levels in patients, with levels rising into the normal range by week 3 of the four-week dosing schedule. The drug was well-...

Jaguar8

Jul 25 07:31

NEWS

$Inozyme Pharma (INZY.US)$
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
Inozyme Pharma (Nasdaq: INZY) has published preclinical data in the journal Cells, supporting the potential of INZ-701, their lead ENPP1 enzyme replacement therapy (ERT) candidate, to treat a broad range of rare diseases affecting bone health and blood vessel function. The study demonstrates IN...

Jaguar8

May 23 07:33

$Inozyme Pharma (INZY.US)$
NEWS
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
Inozyme Pharma (Nasdaq: INZY) announced that it will present topline data from its Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency at two upcoming medical conferences. The presentations will occur at the European Calcified Tissue Society Congress (ECTS)...

Meltyy

Jan 4 01:15

$XBI: Biotech Sector's Potential Outperformance in 2024, Especially Pre-Election Volatility in 1H

$SPDR S&P Biotech ETF (XBI.US)$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...

21

3

INZY Inozyme Pharma

Trade Overview

Capital Trend

News

Comments